Many With Wet AMD Need Ranibizumab Retreatment Even After Year-Long Pause

by Medscape • 2016/04/27 • 0 Comments

Retreatment with ranibizumab is necessary for up to a third of neovascular age-related macular degeneration (AMD) patients who are treatment-free for one year, new research shows.
Reuters Health Information

Full Story →

← Ocular TherapeutixTM Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension

Repeat DSAEK yields similar endothelial cell loss, visual outcomes to primary procedure →

Post navigation